**In the Specification:**

On page 2, line 2, before "This specification is a Continuation of PCT International Application No. PCT/HU8/00086 filed on September 17, 1998, which designated the United States and on which priority is claimed under 35 U.S.C. 120, the entire contents of which are hereby incorporated by reference" (*see* September 18, 2000 Amendment, Remark section, page 15, lines 3-10), please insert the heading --CROSS-REFERENCE WITH OTHER APPLICATIONS--.

C1

On page 2, line 2, after "This specification is a Continuation of PCT International Application No. PCT/HU8/00086 filed on September 17, 1998, which designated the United States and on which priority is claimed under 35 U.S.C. 120, the entire contents of which are hereby incorporated by reference" (*see* September 18, 2000 Amendment, Remark section, page 15, lines 3-10), please insert the heading --FIELD OF THE INVENTION--.

C2

On page 2, after line 26 and before line 27, please insert the heading --BACKGROUND OF THE INVENTION--.

On page 3, after line 8 and before line 9, please insert the heading --BRIEF SUMMARY OF THE INVENTION--.

On page 3, after line 12 and before line 13, please inert the followings:

C5

--BRIEF DESCRIPTION OF THE FIGURES

Figure 1 represents a taxonoid of the general formula I.

Figure 2A shows the mass spectrum of the standard.
Figure 2B shows the curve of the re-dissolved sample.
Figure 2C shows the fragmentation of amphotericin B.

Figure 3A shows the mass spectrum of the standard.
Figure 3B shows the curve of the re-dissolved sample.
Figure 3C shows the fragmentation of carbamazepin.

Figure 4A shows the mass spectrum of the standard.
Figure 4B shows the curve of the re-dissolved sample.
Figure 4C shows the fragmentation of cyclosporine A.

Figure 5A shows the mass spectrum of the standard.
Figure 5B shows the curve of the re-dissolved sample.
Figure 5C shows the fragmentation of the propofol.

Figure 6A shows the mass spectrum of the standard.
Figure 6B shows the curve of the re-dissolved sample.
Figure 6C shows the curve of the fragmentation of paclitaxel.

Figure 7 shows the variation of paclitaxel concentration (with 0.08% HSA, 10% ethanol, 0.2 mg/ml paclitaxel).

Figure 8 shows the variation of paclitaxel binding to HSA (with 0.004%-16% HSA, 20% ethanol, 0.2 paclitaxel).

Figure 9 shows the variation of paclitaxel binding to HSA (with 0.8% HSA, 10% ethanol, 0.1 to 2.0 mg/ml paclitaxel) as a function of pH at values of pH 4.0 to 8.5.--

On page 3, immediately after the newly inserted section titled "BRIEF DESCRIPTION OF THE FIGURES" and before line 13, please insert the heading --DETAILED DESCRIPTION OF THE INVENTION--.

These amendments do not constitute new matter as there is clear support for this amendment is found in the specification (*see also*, September 18, 2000 Amendment, pages 15-16).